Surabhi Dangi-Garimella, PhD

Panelists at the policy summit hosted by National Comprehensive Cancer Network agreed that sharing information can help create a learning system that can improve patient outcomes.

The American Society of Clinical Oncology (ASCO) has published a paper that shares the various innovative approaches developed by the society for guideline development and implementation.

A federal appeals court has overturned a previous ruling and decided that biosimilar manufacturers must provide the innovator company a 180-day notice only after receiving FDA-approval for its biosimilar product.

Researchers from the Duke Cancer Institute have discovered that mutations in the BRCA1 gene can dramatically increase the probability of a woman developing serous or serous-like endometrial carcinoma.

Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit, held just 2 days before the Cancer Moonshot Summit.

At the Cancer Moonshot Summit, Vice President Joe Biden cautioned research scientists to expect funding cuts if they failed to report, in a timely manner, the findings of clinical trials.

CMS has announced that the Oncology Care Model (OCM) developed by the Center for Medicare and Medicaid Innovation has 196 practices and 17 payers enrolled for participation.

A newly formed data-sharing initiative, Oncology Precision Network (OPeN), is promising a boost to precision medicine via data access to several health systems and cancer patients in the nation.

Maximizing the utility of technology platforms and making them meaningful to ensure quality cancer care was the underlying theme of Emerging Issues and Opportunities in Health Information Technology, a National Comprehensive Cancer Network Policy Summit.

A combination of sofosbuvir and velpatasvir (Epclusa) that is effective against all 6 major forms of the hepatitis C virus (HCV) has received the FDA’s consent to market.

Six former FDA commissioners participated in a discussion at the Aspen Ideas Festival on the challenges that the agency faces and whether it is well equipped to do its job.

Exposure of patients to the dangers of certain diagnostic equipment can have unwanted long-term effects, which healthcare providers may be underestimating, according to research conducted at the University of Saskatchewan.

A report developed by Avalere Health, based on a survey that the company conducted among health plans in 2015, states that a majority of health plans want to sign outcomes-based contracts with biopharmaceutical companies, especially for oncology and hepatitis C drugs.

A new study in the New England Journal of Medicine has established that, at least in the case of lymphoma, a positron emission tomography (PET) scan can spare the patients serious side effects of chemotherapy.

A scoping document explaining the review process to evaluate existing treatment options for non-small cell lung cancer (NSCLC) has been released by the Institute for Clinical and Economic Review (ICER).

At the annual meeting of The Community Oncology Alliance, oncologists sat through a crash course on biosimilars that was rendered by experts from the pharmaceutical industry.

At The Community Oncology Conference: Innovation in Cancer Care, oncologists discussed how their practices are coping with the transition toward quality- and value-based reimbursement.

Representatives from 3 clinics that successfully participated in the accreditation process for an Oncology Medical Home, participated on a panel at The Community Oncology Conference: Innovation in Cancer Care.

An expert panel at The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida, April 13-15, 2016, provided insight on current transitions in healthcare reform, and their predictions for the future.

A study assessed the reliability of a 12-gene Recurrence Score test to reveal the natural course of recurrence among Japanese patients with stage II and III colon cancer who have undergone surgery but not received any adjuvant chemotherapy.

If the announcement by the Swiss pharmaceutical giant Novartis holds true, biosimilars that the company plans to launch over the next 4 years could create a significant dent in the sales of 5 blockbuster molecules in the oncology and immunology space.

Improving the healthcare services that an organization provides can be challenging unless one gathers information on the service, collates it, improves on it, and implements the changes in the field. A panel of experts invited by Evidence-Based Oncology discussed processes that help identify the most valuable metrics and the importance of making them relevant for use in the clinic.

Growing antibiotic resistance is a significant global problem. But steps are being taken to apply brakes on the rise of "superbugs."

The new guideline, similar to the previous version, recommends screening for CRC for those 50 to 75 years of age and leaves the decision for screening in those 76 to 85 years of age on the individual. However, for the 50 to 75 age group, the USPSTF leaves the choice of the test on the individual, which is a departure from the previous guideline.

According to research published in the journal Clinical Cancer Research, immunotherapy right after chemotherapy can piggy back on the immune modifications caused by the chemotherapy, to improve response to treatment in ovarian cancer.

Healthcare providers are facing a syndrome called “EHR alert fatigue,” a product of the constant bombardment of health alerts on electronic health records (EHRs). How are providers and health systems reacting to this issue?

A collaborative effort by urologists and public health specialists from various healthcare systems around the country has found that PSA levels measured in midlife (45 to 59 years of age) are a strong predictor of future lethal prostate cancer.

A new study, published in the Journal of Thoracic Oncology, has found that chemotherapy administered in patients with stage I disease, following a complete resection, can have a significant impact on their median 5-year overall survival.

A survey conducted among members of the South Carolina Academy of Family Physicians found that although most family physicians reported that they discussed low-dose computed tomography screening (LDCT) with their patients, referrals were low

The Colombian government is forcing pharmaceutical giant Novartis to lower prices of its leukemia medicine, imatinib (Gleevec).